Literature DB >> 7325471

Pharmacokinetics of naproxen in the dog.

H H Frey, B Rieh.   

Abstract

The pharmacokinetics of naproxen was studied in mongrel dogs. After IV injection of a 5 mg/kg dose, plasma concentrations decreased biexponentially, with an average elimination half-life of 74 hours. The drug was highly protein-bound (greater than 99%) and had a correspondingly low apparent volume of distribution (0.13 L/kg). After naproxen was given orally, absorption was rapid, and the bioavailability ranged between 68% and 100%. With an initial dose of 5 mg/kg given orally, therapeutic plasma concentrations could be maintained by giving 1 daily dose of 1.2 to 2.8 mg/kg.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7325471

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  4 in total

1.  Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls.

Authors:  Mark G Papich; Marilyn N Martinez
Journal:  AAPS J       Date:  2015-04-29       Impact factor: 4.009

2.  The effect of surgery (Ovariohysterectomy) on the plasma disposition of meloxicam following intravenous administration in dogs.

Authors:  Umit Karademir; Dilek Aksit; Cavit Kum; Hasan Erdogan; Eyup Hakan Ucar; Cevdet Peker; Cengiz Gokbulut
Journal:  BMC Vet Res       Date:  2016-02-20       Impact factor: 2.741

3.  Treatment of a massive naproxen overdose with therapeutic plasma exchange in a dog.

Authors:  Kathleen Kicera-Temple; Leonel Londoño; Travis M Lanaux; Gareth J Buckley
Journal:  Clin Case Rep       Date:  2019-06-28

4.  Outcomes of nonsteroidal anti-inflammatory drug toxicosis treated with therapeutic plasma exchange in 62 dogs.

Authors:  Emmanuelle M Butty; Steven E Suter; Nolan V Chalifoux; Alex M Lynch; Katie D Mauro; Rachel B Moyle; Caryn M Ehrhardt; James B Robertson; Christine A Culler; Leonel A Londoño; Alessio Vigani; Yu Ueda; Mary A Labato
Journal:  J Vet Intern Med       Date:  2022-08-05       Impact factor: 3.175

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.